Cargando…

Prothymosin α and a prothymosin α-derived peptide enhance T(H)1-type immune responses against defined HER-2/neu epitopes

BACKGROUND: Active cancer immunotherapies are beginning to yield clinical benefit, especially those using peptide-pulsed dendritic cells (DCs). Different adjuvants, including Toll-like receptor (TLR) agonists, commonly co-administered to cancer patients as part of a DC-based vaccine, are being widel...

Descripción completa

Detalles Bibliográficos
Autores principales: Ioannou, Kyriaki, Derhovanessian, Evelyna, Tsakiri, Eleni, Samara, Pinelopi, Kalbacher, Hubert, Voelter, Wolfgang, Trougakos, Ioannis P, Pawelec, Graham, Tsitsilonis, Ourania E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3852324/
https://www.ncbi.nlm.nih.gov/pubmed/24053720
http://dx.doi.org/10.1186/1471-2172-14-43